Search This Blog

Monday, January 28, 2019

Train the brain to form good habits through repetition


You can hack your brain to form good habits — like going to the gym and eating healthily — simply by repeating actions until they stick, according to new psychological research involving the University of Warwick.
Dr Elliot Ludvig from Warwick’s Department of Psychology, with colleagues at Princeton and Brown Universities, have created a model which shows that forming good (and bad) habits depends more on how often you perform an action than on how much satisfaction you get from it.
The new study is published in Psychological Review.
The researchers developed a computer simulation, in which digital rodents were given a choice of two levers, one of which was associated with the chance of getting a reward. The lever with the reward was the ‘correct’ one, and the lever without was the ‘wrong’ one.
The chance of getting a reward was swapped between the two levers, and the simulated rodents were trained to choose the ‘correct’ one.
When the digital rodents were trained for a short time, they managed to choose the new, ‘correct’ lever when the chance of reward was swapped. However, when they were trained extensively on one lever, the digital rats stuck to the ‘wrong’ lever stubbornly, even when it no longer had the chance for reward.
The rodents preferred to stick to the repeated action that they were used to, rather than have the chance for a reward.
Dr Elliot Ludvig, Associate Professor in the University of Warwick’s Department of Psychology and one of the paper’s authors, commented:
“Much of what we do is driven by habits, yet how habits are learned and formed is still somewhat mysterious. Our work sheds new light on this question by building a mathematical model of how simple repetition can lead to the types of habits we see in people and other creatures. ”
Dr Amitai Shenhav, Assistant Professor in Brown University’s Department of Cognitive, Linguistic, and Psychological Sciences and one of the paper’s authors, commented:
“Psychologists have been trying to understand what drives our habits for over a century, and one of the recurring questions is how much habits are a product of what we want versus what we do. Our model helps to answer that by suggesting that habits themselves are a product of our previous actions, but in certain situations those habits can be supplanted by our desire to get the best outcome.”
This research opens up a better understanding of conditions like Obsessive Compulsive Disorder and Tic Disorder — both of which are characterised by repeated behaviours.
The next stage will be to conduct similar experiments in a real-world scenario, observing human behaviour in action-based versus reward-based tests.
Story Source:
Materials provided by University of WarwickNote: Content may be edited for style and length.

Journal Reference:
  1. Kevin J. Miller, Amitai Shenhav and Elliot A. Ludvig. Habits Without ValuesPsychological Review, 2018 DOI: 10.1101/067603

New guidelines for atrial fibrillation recommend new class of blood thinners


A newer type of blood-thinning medications, non-vitamin K oral anticoagulants (NOACs), is now recommended as the preferred alternative to warfarin for reducing the risk of stroke associated with atrial fibrillation (AFib), according to a focused update to the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline for the Management of Patients With Atrial Fibrillation.
AFib is a type of irregular heartbeat in the atria, or upper chambers of the heart. Because the heart beat is irregular, blood can pool and then clot inside the atria, particularly in the left atrial appendage, a pouch that is part of the anatomy of the upper left chamber of the heart. If the clots formed within the left atrium migrate within the blood and reach the brain, a stroke caused by a blocked artery can occur even in people with no obvious symptoms of AFib.
Blood-thinning medications called anticoagulants have long been recommended to reduce the risk of stroke in patients with AFib who have an increased risk of thromboembolism (blockage of a blood vessel by a clot travelling in the bloodstream) and/or stroke caused by narrowed or blocked arteries
To reduce stroke risk in appropriate AFib patients, a newer class of anticoagulants known as NOACs is now the preferred recommended drug class over the traditional medication warfarin, unless patients have moderate to severe mitral stenosis (narrowing of the mitral valve) or have an artificial heart valve. NOACs include dabigatran, rivaroxaban, apixaban and edoxaban.
“Patients with AFib are at increased risk of stroke, which can be devastating. A goal of treating AFib patients is to make blood less likely to form clots, which reduces the risk of stroke. New scientific studies show that NOACs may be safer for patients because there is less risk of bleeding, and they may also be more effective at preventing blood clots than warfarin,” said Craig T. January, M.D., Ph.D., co-chair of the focused update published simultaneously in the American Heart Association journal Circulation, Journal of the American College of Cardiology and the Heart Rhythm Society journal, HeartRhythm.
Guidelines rank recommendations as strong, weak, or harmful on the basis of the quality and quantity of the scientific research that supports each recommendation. Recommendations with the highest level of evidence have more than one randomized controlled trial reporting similar results, whereas the lowest-ranked recommendations are based on the clinical experience of experts. Along with the strong recommendation to use NOACs in favor of warfarin for many patients, the new guidelines recommend:
Weight loss for overweight or obese patients. Studies find that losing weight can reduce the health risks associated with or even reverse AFib. It can also lower blood pressure (high blood pressure is often associated with AFib).
New drugs are available to reverse the effect of NOACs (called reversal agents). These reversal agents, while used infrequently, are helpful when there are signs of severe bleeding caused by a NOAC or when a patient on a NOAC needs an emergency surgical procedure.
“AFib patients should talk to their healthcare provider about any concerns they have about their prescribed medications and whether or not losing weight would benefit their health,” said January, who is professor of cardiovascular medicine at the University of Wisconsin in Madison, Wisconsin.
The new guidelines also suggest that NOACs could even be used in people at lower risk of stroke than previously thought. Although the evidence for this recommendation is not yet definitive, emerging research is beginning to suggest that the benefit of NOACs for reducing stroke risk outweighs the risk of taking them, said January.
Story Source:
Materials provided by American Heart AssociationNote: Content may be edited for style and length.

Journal Reference:
  1. Craig T. January, L. Samuel Wann, Hugh Calkins, Lin Y. Chen, Joaquin E. Cigarroa, Joseph C. Cleveland, Patrick T. Ellinor, Michael D. Ezekowitz, Michael E. Field, Karen L. Furie, Paul A. Heidenreich, Katherine T. Murray, Julie B. Shea, Cynthia M. Tracy, Clyde W. Yancy. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial FibrillationCirculation, 2019; DOI: 10.1161/CIR.0000000000000665

InflaRx initiated with an Outperform at Baird


Baird initiated InflaRX with an Outperform and $62 price target.

D.E. Shaw takes 5.1% passive stake in Lannett


D.E. Shaw disclosed a 5.1% passive stake in Lannett. The stake represents just under 2.0M shares. The filing with the SEC does not allow for activism.
https://thefly.com/landingPageNews.php?id=2854753

U.S. judge to allow controversial evidence in Roundup cancer trials


A federal judge overseeing lawsuits alleging Bayer AG’s glyphosate-based Roundup weed killer causes cancer on Monday tentatively allowed pieces of controversial evidence that the company had hoped to exclude from upcoming trials.
U.S. District Judge Vince Chhabria during a hearing in San Francisco federal court called his decision “probably most disappointing for Monsanto,” the Bayer unit that manufactures the world’s most widely used herbicide.
The company denies allegations that glyphosate causes cancer and says decades of independent studies have shown the chemical to be safe for human use.

Chhabria on Monday said plaintiffs could introduce some evidence of Monsanto’s alleged attempts to ghostwrite studies and influence the findings of scientists and regulators during the first phase of upcoming trials. He said documents which showed the company taking a position on the science or a study introduced during the first phase were “super relevant.”
The company had hoped the judge would take a harder line on such evidence following a Jan. 3 order by Chhabria restricting evidence of corporate misconduct. At the time, that decision lifted Bayer’s shares nearly 7 percent.
Monsanto had argued much of this evidence was a “sideshow” that would only distract jurors from the scientific evidence.
Plaintiffs’ lawyers contended some evidence of corporate misconduct was inextricably linked to their scientific claims.
The judge appeared to agree with them, saying it was difficult to draw the line between scientific evidence and allegations of corporate misconduct, and questioned whether it would be fair for the jury to not hear about the company’s alleged attempts to influence scientists.
The parties did agree that other internal documents, including emails of Monsanto employees discussing lobbying efforts, do not belong in the initial trial phase.
Under Chhabria’s order, that evidence would be allowed only if glyphosate was found to have caused plaintiff Edwin Hardeman’s cancer and the trial proceeded to a second phase to determine Bayer’s liability.
The order applies to Hardeman’s case, which is scheduled to go to trial on Feb. 25, and two other upcoming cases. There are some 620 Roundup cases before Chhabria, out of more than 9,300 nationwide.
Plaintiffs’ lawyers believe corporate misconduct evidence was critical to a California state court jury’s August decision to award $289 million in a similar case. The verdict sent Bayer shares tumbling at the time, though the award was later reduced to $78 million and is under appeal.

Why Cronos Group Gained


Shares of Cronos Group (NASDAQ:CRON) soared 14.1% as of 3:16 p.m. EST on Monday. The marijuana stock appeared to receive a boost from U.S. attorney general nominee William Barr’s written response to questions from the Senate Judiciary Committee. In this response, Barr confirmed his previous testimony before the committee that he would not target cannabis businesses that comply with individual states’ marijuana laws.

Cronos wasn’t the only Canadian marijuana stock to jump after Barr’s written pledge made news. Several of the company’s peers also enjoyed nice gains on Monday, including Aurora CannabisCanopy Growth, and Tilray.
But none of the other top marijuana stocks moved as much as Cronos did. That’s possibly because Cronos claims a lower market cap than others and could be perceived as a more attractive bargain by investors.
There’s also the fact that — other than Canopy Growth, which claims a market cap more than five times greater than Cronos — only Cronos Group has landed a big investment from a major partner outside the cannabis industry. In December, tobacco giant Altria bought a 38% stake in Cronos for $1.8 billion.
Did the written statement from Barr justify such a major rise for Cronos? Not really. As of now, Cronos and the other major Canadian marijuana growers can’t establish operations in the U.S. marijuana market and retain their listings on U.S. stock exchanges or the Toronto Stock Exchange.
However, Barr’s written response indicates that the Trump administration won’t be hostile toward the cannabis industry. That’s potentially good news for Canadian companies that plan to enter the U.S. hemp market following the recent legalization of hemp in the U.S. It also reinforces optimism that the administration might support congressional efforts to revise federal laws in a way that would allow Canadian companies to legally operate in the U.S. marijuana market.

Investors will certainly want to watch if Cronos Group makes any moves to enter the U.S. hemp market. Such an expansion would likely be made in lockstep with Altria.
In the meantime, the most important thing for Cronos is executing on its strategy in the Canadian recreational marijuana market. The company posted huge revenue growth in Q3, but its numbers didn’t include any sales from recreational marijuana products. When Cronos reports its next quarterly results, investors should have a lot more to cheer about.

Revance initiated with a Buy at Stifel


Stifel analyst Annabel Samimy initiated Revance (RVNC) with a Buy rating and $50 price target, citing her view that the company’s daxibotulinumtoxinA represents “one of the first truly novel neurotoxin formulations” and potentially offers six-month duration of effect as compared to the 3-4 months for Allergan’s (AGN) Botox and competitors’ agents.